- This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -
- The Company recently entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 for the treatment of axillary hyperhidrosis -
- The Company also has an issued patent in Japan covering their DMT410 program for the treatment of hyperhidrosis -
Read More- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial has enrolled over 50% of patients
- Dermata continues discussions with potential botulinum toxin partners for DMT410
- Raised $2.3 million in net proceeds from financing completed in 2Q 2024
Read More